Investigation of dabigatran secretion into breast milk: Implications for oral thromboprophylaxis in post‐partum women

Abstract

REFERENCES 1. Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394 (10192):29-38. 2. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International staging system for multiple myeloma: a report from International myeloma working group. J Clin Oncol. 2015;33:2863-2869. 3. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-3420. 4. Malavasi F, Funaro A, Roggero S, Horenstein A, Calosso L, Mehta K. Human CD38: a glycoprotein in search of a function. Immunol Today. 1994;15:95-97. 5. Malavasi F, Caligaris-Cappio F, Milanese C, Dellabona P, Richiardi P, Carbonara AO. Characterization of a murine monoclonal antibody specific for human early lymphohemopoietic cells. Hum Immunol. 1984;9:9-20. 6. Xu XS, Dimopoulos MA, Sonneveld P, et al. Pharmacokinetics and exposure-response analyses of Daratumumab in combination therapy regimens for patients with multiple myeloma. Adv Ther. 2018;35:18591872.